Drug Trial Radar · NCT04930536
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Jul 14, 2021
Primary completion
May 2, 2023
Study completion May 2, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
Conditions
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Interventions
Acalabrutinib capsuleDrug
The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, InfectionsTime frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])
- Second Primary MalignanciesTime frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Ahmedabad, India
Research Site
Bangalore, India
Research Site
Bangalore, India
Research Site
Bengaluru, India
Research Site
Chandigarh, India
Research Site
Gurugram, India
Research Site
Guwahati, India
Research Site
Hyderabad, India
Research Site
Hyderabad, India
Research Site
Kochi, India
Research Site
Kolkata, India
Research Site
Ludhiana, India
Research Site
Mumbai, India
Research Site
Mumbai, India
Research Site
New Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.